A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

NCT06287918 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors With FGFR2 Alterations, Adult

Interventions

DRUG: 3HP-2827

Sponsor

3H (Suzhou) Pharmaceuticals Co., Ltd.